Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Relay Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Relay Therapeutics, Inc.’s stock price such as:

• Relay Therapeutics, Inc.’s current stock price and volume
• Why Relay Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for RLAY from analysts
• RLAY’s stock price momentum as measured by its relative strength

About Relay Therapeutics, Inc. (RLAY)

Before we jump into Relay Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Relay Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Relay Therapeutics, Inc..

Relay Therapeutics, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, Relay Therapeutics, Inc.’s stock price was $8.030.

Relay Therapeutics, Inc. is down 0.25% from its previous closing price of $8.050.

During the last market session, Relay Therapeutics, Inc.’s stock traded between $7.860 and $8.170. Currently, there are approximately 172.39 million shares outstanding for Relay Therapeutics, Inc..

Relay Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Relay Therapeutics, Inc. Stock Price History

Relay Therapeutics, Inc.’s (RLAY) price is currently up 12.47% so far this month.

During the month of November, Relay Therapeutics, Inc.’s stock price has reached a high of $8.360 and a low of $5.950.

Over the last year, Relay Therapeutics, Inc. has hit prices as high as $8.360 and as low as $1.775. Year to date, Relay Therapeutics, Inc.’s stock is up 94.9%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Relay Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 25, 2025, there was 1 analyst who downgraded Relay Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Relay Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Relay Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Relay Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Relay Therapeutics, Inc. (RLAY) by visiting AAII Stock Evaluator.

Relative Price Strength of Relay Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 25, 2025, Relay Therapeutics, Inc. has a weighted four-quarter relative price strength of 38.50%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Relay Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Relay Therapeutics, Inc. Stock Price: Bottom Line

As of November 26, 2025, Relay Therapeutics, Inc.’s stock price is $8.030, which is down 0.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Relay Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.